Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia

Summary

Endocrine disorders affect both the coagulation and fibrinolytic systems, and have been associated with the development of cardiovascular diseases. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a link between coagulation and the fibrinolytic system. The aim of this study was to determine the effect of thyroid hormone excess and deficiency on TAFI levels and function. The effect of hyperthyroxinemia on TAFI was studied in healthy volunteers who were randomised to receive levothyroxine or no medication for 14 days in a crossover design. The effect of hypothyroidism on TAFI was studied in a multicentre observational cohort study. Blood was drawn before treatment of patients with newly diagnosed hypothyroidism and when euthyroidism was achieved. Plasma clot-lysis times, activated TAFI (TAFIa)-dependent prolongation of clot-lysis and TAFI levels were measured. Thyroid hormone excess resulted in a hypofibrinolytic condition and in an enhanced TAFIa-dependent prolongation of clot lysis. A trend towards decreased plasma TAFI levels was observed in healthy volunteers who used levothyroxine. Hypothyroidism resulted in hyperfibrinolysis and a reduced TAFIa-dependent prolongation of clot lysis. In conclusion, alterations of TAFIa-dependent prolongation of clot lysis in patients with thyroid disorders may cause an impaired haemostatic balance. The disturbed haemostatic balance in patients with hyperthyroidism might make them prone to thrombosis, while the risk for bleeding may increase in patients with hypothyroidism.

Keywords

TAFI - thyroid - fibrinolysis - coagulation

• References

• 1 Ladenson PW. Recognition and management of cardiovascular disease related to thyroid dysfunction. Am J Med 1990; 88: 638-641.
• 2 Vanderpump MP, Tunbridge WM, French JM. et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995; 43: 55-68.
• 3 Hak AE, Pols HA, Visser TJ. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132: 270-278.
• 4 Muller B, Tsakiris DA, Roth CB. et al. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest 2001; 31: 131-137.
• 5 Squizzato A, Gerdes VE, Brandjes DP. et al. Thyroid diseases and cerebrovascular disease. Stroke 2005; 36: 2302-2310.
• 6 Squizzato A, Romualdi E, Buller HR. et al. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-2420.
• 7 Burggraaf J, Lalezari S, Emeis JJ. et al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001; 11: 153-160.
• 8 Dorr M, Robinson DM, Wallaschofski H. et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab 2006; 91: 530-534.
• 9 Erem C, Ersoz HO, Karti SS. et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002; 25: 345-350.
• 10 Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol 2006; 64: 323-329.
• 11 Homoncik M, Gessl A, Ferlitsch A. et al. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab 2007; 92: 3006-3012.
• 12 Dalton RG, Dewar MS, Savidge GF. et al. Hypothyroidism as a cause of acquired von Willebrand’s disease. Lancet 1987; 01: 1007-1009.
• 13 Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol 2005; 152: 355-361.
• 14 Erem C, Kavgaci H, Ersoz HO. et al. Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract 2003; 57: 78-81.
• 15 Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid dysfunction. N Engl J Med 1965; 273: 1057-1061.
• 16 Chadarevian R, Bruckert E, Leenhardt L. et al. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001; 86: 732-737.
• 17 Franchini M, Montagnana M, Manzato F. et al. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009; 35: 288-294.
• 18 Marx PF, Verkleij CJ, Seron MV. et al. Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research. Mini Rev Med Chem 2009; 09: 1165-1173.
• 19 Emonts M, de Bruijne EL, Guimaraes AH. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 2008; 06: 268-276.
• 20 Guimaraes AH, Laurens N, Weijers EM. et al. TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27: 2157-2162.
• 21 Te Velde EA, Wagenaar GT, Reijerkerk A. et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 01: 2087-2096.
• 22 Akinci B, Comlekci A, Ali OM. et al. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement. Endocr J 2007; 54: 45-52.
• 23 Cetinkalp S, Tobu M, Karadeniz M. et al. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis. Intern Med 2009; 48: 281-285.
• 24 Erem C, Ucuncu O, Yilmaz M. et al. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism. Endocrine 2009; 35: 75-80.
• 25 Ermantas N, Guldiken S, Demir M. et al. Thrombin -Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidism. Clin Appl Thromb Hemost 2010; 16: 568-573.
• 26 Akinci B, Comlekci A, Yener S. et al. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients. Endocr J 2007; 54: 593-599.
• 27 Erem C, Ucuncu O, Yilmaz M. et al. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism. Endocrine 2009; 36: 473-478.
• 28 Akinci B, Demir T, Comlekci A. et al. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules. Med Princ Pract 2011; 20: 23-28.
• 29 Van Zaane B, Squizzato A, Debeij J. et al. Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. J Thromb Haemost 2011; 09: 1816-1824.
• 30 Mosnier LO, Von dem Borne PA, Meijers JC. et al. Plasma TAFI levels determine the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
• 31 Willemse J, Leurs J, Verkerk R. et al. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate. Anal Biochem 2005; 340: 106-112.
• 32 Zorio E, Castello R, Falco C. et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003; 122: 958-965.
• 33 Zeerleder S, Schroeder V, Hack CE. et al. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-212.